A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Latest Information Update: 09 May 2024
At a glance
- Drugs Canakinumab (Primary)
- Indications Anaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
Most Recent Events
- 03 May 2024 Status changed from recruiting to discontinued.
- 17 May 2022 Status changed from not yet recruiting to recruiting.
- 31 Mar 2022 Planned initiation date changed from 1 Mar 2022 to 15 Apr 2022.